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Abstract 
Mitochondria play a key role in the homeostasis of the vast majority of the body’s cells. In the myocardium where 
mitochondria constitute 30 % of the total myocardial cell volume, temporary attenuation or obstruction of blood flow 
and as a result oxygen delivery to myocardial cells (ischemia) severely alters mitochondrial structure and function. 
These alterations in mitochondrial structure and function occur during ischemia and continue after blood flow and 
oxygen delivery to the myocardium is restored, and significantly decrease myocardial contractile function and myo-
cardial cell survival. We hypothesized that the augmentation or replacement of mitochondria damaged by ischemia 
would provide a mechanism to enhance cellular function and cellular rescue following the restoration of blood flow. 
To test this hypothesis we have used a model of myocardial ischemia and reperfusion. Our studies demonstrate that 
the transplantation of autologous mitochondria, isolated from the patient’s own body, and then directly injected into 
the myocardial during early reperfusion augment the function of native mitochondria damaged during ischemia 
and enhances myocardial post-ischemic functional recovery and cellular viability. The transplanted mitochondria act 
both extracellularly and intracellularly. Extracellularly, the transplanted mitochondria enhance high energy synthesis 
and cellular adenosine triphosphate stores and alter the myocardial proteome. Once internalized the transplanted 
mitochondria rescue cellular function and replace damaged mitochondrial DNA. There is no immune or auto-immune 
reaction and there is no pro-arrhythmia as a result of the transplanted mitochondria. Our studies and those of others 
demonstrate that mitochondrial transplantation can be effective in a number of cell types and diseases. These include 
cardiac and skeletal muscle, pulmonary and hepatic tissue and cells and in neuronal tissue. In this review we discuss 
the mechanisms leading to mitochondrial dysfunction and the effects on cellular function. We provide a methodol-
ogy for the isolation of mitochondria to allow for clinical relevance and we discuss the methods we and others have 
used for the uptake and internalization of mitochondria. We foresee that mitochondrial transplantation will be a 
valued treatment in the armamentarium of all clinicians and surgeons for the treatment of varied ischemic disorders, 
mitochondrial diseases and related disorders.
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Introduction
Mitochondria are unique organelles containing their own 
DNA that encodes the mitochondrial subunits of the oxi-
dative phosphorylation system. The role of the mitochon-
dria has primarily been considered to be that of energy 
production and synthesis through fermentation and gly-
colysis with most of the energy requirements of the cell 
being derived through the electron transport chain and 
oxidative phosphorylation [1].
In the myocardium mitochondria constitute 30  % of 
the total myocardial cell volume and play an important 
role in the maintenance and modulation of organ func-
tion. The mitochondria provide for the majority of cel-
lular energy to the heart and are dependent upon a 
continuous supply of oxygen delivered by the coronary 
arteries to maintain the energy requirements of the myo-
cardial cells. The attenuation or cessation of coronary 
blood flow decreases oxygen delivery to the myocardium 
(myocardial ischemia) and induces a cascade of cellular 
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events which rapidly alter mitochondrial function lead-
ing to myocardial cellular dysfunction and/or cell death 
and myocardial contractile functional impairment that 
extends after the restoration of coronary blood flow to 
the heart [2–9].
Herein we will review the role of the mitochondria in 
the myocardium following myocardial ischemia and pro-
vide evidence to show that the augmentation or replace-
ment of mitochondria is efficacious. To this end, we have 
proposed a robust therapeutic intervention to ameliorate 
myocardial ischemia and significantly decrease morbid-
ity and mortality in the myocardium following ischemia, 
by direct injection of autologous mitochondria, isolated 
from non-ischemic tissue obtained from the patient’s 
own body and then directly injected into the ischemic 
myocardium. In this review we discuss the rationale and 
efficacy of mitochondrial transplantation and provide 
evidence for alternative usage.
Review
A significant body of evidence now exists to show that 
in addition to high energy synthesis, the mitochon-
drion plays an important role in regulating a variety of 
diseases and genetic disorders [2]. In a series of studies 
using animal models we and others have demonstrated 
that ischemia occurring through decreased blood flow 
to the myocardium significantly alters myocardial mito-
chondrial structure and function [3–9]. These alterations 
while occurring during ischemia persist after the restora-
tion of blood flow and oxygen delivery to the heart and 
are associated with significantly decreased myocardial 
function and myocardial cell survival [3–6].
The mechanisms for these alterations in function are 
varied. In studies extending over 25 years, we have shown 
that ischemia significantly increases myocardial cytoplas-
mic calcium accumulation and that this increase results 
in significantly increased mitochondrial calcium accumu-
lation and significantly increases mitochondrial volume 
[3–7]. The mechanism modulating increased mitochon-
drial volume is directly related to mitochondrial calcium 
handling. Under homeostatic conditions, the mitochon-
drial inner membrane containing the electron transport 
chain expels protons to the cytosol, creating a charge gra-
dient that provides the passive energy for calcium influx 
to the mitochondrion by the calcium uniporter. Follow-
ing ischemia, the increased cytosolic calcium accumula-
tion is taken up in the mitochondrion. The increase in 
mitochondrial calcium destabilizes the inner mitochon-
drial membrane, and causes the inner membrane pore 
to open and permit further cation movement. This pro-
cess is referred to as “futile calcium cycling”, an energy 
dependent process requiring high energy phosphates 
(ATP) to transport calcium against the electrochemical 
gradient out of the mitochondrion [3–6]. As calcium 
enters the mitochondria, water follows leading to mito-
chondrial matrix swelling and eventually mitochondrial 
rupture and myocardial cell dysfunction [7].
In the isolated perfused heart and in the in vivo pig and 
sheep model of regional and global ischemia and reperfu-
sion, we and others have shown that following 20–30 min 
of myocardial ischemia the matrix and cristae of mito-
chondria in the heart are severely swollen (Fig. 1) [6–8].
It has been estimated that greater than 88  % of myo-
cardial mitochondria are swollen following 20–30 min of 
ischemia and exhibit increased intermembrane space and 
swollen cristae and disrupted matrix [6, 9]. We have con-
firmed these changes in mitochondrial structure using 
both transmission electron microscopy and the light scat-
tering technique [6, 9]. Transmission electron micros-
copy of greater than 500 mitochondria from each tissue 
source revealed that the ischemic myocardial mitochon-
dria are electron translucent and swollen as compared to 
mitochondria from non-ischemic areas [6].
Light scattering was also used to determine changes in 
mitochondrial volume. The light scattering technique is 
sensitive to changes in the intermembrane space and the 
shape of mitochondria, premised upon the observation 
that swollen mitochondria are associated with a decrease 
in light absorbance. Mitochondrial matrix volume was 
measured as the decrease in absorbance at 520  nm, the 
isosbestic point for the mitochondrial cytochromes, 
allowing for the estimation of volume insensitive to 
changes in redox state [6]. Our studies using light scat-
tering demonstrated that ischemic myocardial mito-
chondria are swollen as compared to non-ischemic 
mitochondria [6].
These alterations in mitochondrial structure have been 
proposed to play a leading role in diminished mitochon-
drial oxygen consumption and high energy synthesis. 
Under normoxic conditions the electron transport chain 
allows for the active transport of hydrogen ions across 
the inner mitochondrial membrane, out of the matrix 
to the intermembrane space, creating an electrochemi-
cal gradient [10]. This gradient provides the energy that 
allows the release of ATP from ATP synthase and export 
to the cytosol. This export is regulated by the ATP/ADP 
translocator (ANT), mitochondrial creatine kinase (Mi-
CK) and the voltage dependent anion channel (VDAC) 
[10]. The space between the outer and the inner mito-
chondrial membrane is bridged by Mi-CK in close con-
tact with VDAC and ANT. The close association between 
VDAC, ANT and MI-CK confers a low permeability to 
nucleotides and requires a narrow intermembrane dis-
tance [11]. It has been proposed that mitochondrial 
swelling would increase intermembrane distance and dis-
sociate the functional interaction between VDAC, ANT 
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and MI-CK thus compromising efficient energy transfer 
during reperfusion and decrease high energy synthesis in 
the myocardium [11].
Our studies in large and small animal have also shown 
that following ischemia, myocardial mitochondrial oxy-
gen consumption is significantly decreased [6.8]. Mito-
chondrial function assessed by oximetry demonstrated 
that state three oxygen consumption and respiratory con-
trol index in malate (complex I substrate) and succinate 
(complex II substrate) energized myocardial mitochon-
dria were significantly decreased (p  <  0.05) as com-
pared to control myocardial mitochondria which did not 
undergo ischemia [6, 8].
One enzyme which may be an indicator of impaired 
mitochondrial function is cytochrome oxidase. 
Cytochrome oxidase is the terminal enzyme complex of 
the inner mitochondrial electron transport chain and 
has been shown to be vital in the production of high 
energy phosphate. Our studies have shown that following 
ischemia cytochrome oxidase mRNA levels and enzyme 
activity (Vmax) is significantly decreased [4, 5]. This 
decrease in cytochrome oxidase would contribute to the 
diminishment of high energy phosphates.
Support for this mechanism comes from 31P nuclear 
magnetic resonance (NMR) studies in the isolated per-
fused rabbit heart where we have shown that ischemia 
induces a significant decrease in phosphocreatine, inor-
ganic phosphate, high energy stores, and high energy 
synthesis [12]. The decrease in high energy stores needed 
for myocardial hemodynamic function occurs during 
ischemia and persists after blood flow and oxygena-
tion of the myocardial tissue is re-established [12]. Our 
studies demonstrate that high energy levels are signifi-
cantly decreased to 36 ± 3 % of control following 30 min 
ischemia and remain significantly decreased at 15  min 
after the restoration of blood flow and oxygenation of 
myocardial tissue is re-established [12]. All these events 
are associated with significantly decreased myocardial 
function [12].
Ischemia also affects the mitochondrial genome and 
mitochondrial transcript and protein synthesis. In human 
studies we have shown that myocardial ischemia results 
in significant damage to the mitochondrial genome [13]. 
Using primer-shift PCR analysis of human tissue samples 
we demonstrated that following ischemia there is a large 
mitochondrial DNA (mtDNA) deletion (approximately 
7.3 kb) that encompasses the region encoding 11 electron 
transport protein subunits [13]. These include 5 of the 7 
protein subunits of complex I (ND3, ND4, ND4L, ND5, 
ND6), the one mitochondrial encoded protein subunit in 
complex III (cyt b), 1 of the 3 protein subunits in com-
plex IV (cytochrome oxidase III) and 1 of the 3 subunits 
in complex V (ATPase 6) [12]. The mtDNA breakpoints 
associated with this deletion are located in the ATP syn-
thase eight gene and in the cytochrome b gene and are 
flanked by four direct repeat sequences. This mtDNA 
Fig. 1 Mitochondrial damage following ischemia. Representative transmission electron photomicrographs from left ventricular tissue from Control 
(non-ischemic) and Ischemia (30 min ischemia) hearts. In Control hearts sarcomere structure is preserved and mitochondria have electron dense 
intracristae matrix and normal size. In Ischemia hearts there is separation myofilaments and severely swollen and electron transparent mitochondria 
containing numerous mitochondrial calcium granules. Calcium granules (Ca2+), mitochondrion (M), sarcomere (S) and nucleus (N) are indicated. 
Scale bars (2 um are shown)
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region has been previously reported to be a major hot-
spot for deletion in the rat [14]. Proximal to the 5′ dele-
tion breakpoint is a 13  bp sequence (located between 
nucleotides 8470–8482) that has been previously iden-
tified to be associated with the mitochondrial disorders 
of Kearns-Sayre syndrome, chronic progressive external 
ophthalmoplegia and Leber’s hereditary optic neuropa-
thy, suggesting that this is hot-spot may be of importance 
in the onset and disability associated with mitochondrial 
associated genetic diseases and syndromes [14]. Interest-
ingly, the 7.3 kb mtDNA deletion is apparent in patients 
with clinical indications of poor recovery following car-
diac surgery suggesting that mtDNA deletions may pro-
vide an important indicator to surgical outcome in the 
cardiac surgical patient population [14].
These changes also affect the nuclear and mitochon-
drial transcript and proteome. Previous studies have 
shown that there is a close association between nuclear 
and mitochondrial transcription and the nuclear and 
mitochondrial proteome [15]. This association is 
apparent with the interrelated actions of nuclear and 
mitochondrial transcription and translation of the mito-
chondrial electron transport chain.
The human mitochondrial genome is a 16,569 base 
pair circular molecule, with approximately 4.6 copies 
per mitochondrion, consisting of two strands, a guanine-
rich strand, the heavy strand (H-strand) and a cytosine-
rich strand, the light strand (L-strand). The heavy strand 
encodes 28 genes, and the light strand encodes night 
genes. These genes include the coding regions for 12S 
and 16S rRNA, 22 tRNAs, and the 13 hydrophobic pro-
teins of the electron transport chain [1].
The mitochondrial electron transport chain consists 
of five tightly linked tandem associated complexes (com-
plexes I–V) residing within the mitochondrial inner 
membrane. The complexes of the electron transport chain 
consist of 76 protein subunits. Thirteen of these 76 pro-
tein subunits are encoded by mtDNA and include seven 
protein subunits in complex I (ND1, ND2, ND3, ND4, 
ND4L, ND5, ND6); 1 subunit in complex III (cytochrome 
b); three subunits in complex IV (cytochrome oxidases I, 
II, III); and three subunits in complex V (ATPase 6, 8).
Complex II, coenzyme Q10, cytochrome c and the vast 
majority of the remaining protein subunits of the elec-
tron transport chain are encoded by nuclear DNA [1].
In animal studies, we have found that myocardial 
ischemia induces significant alterations in nuclear and 
mitochondrial transcriptomic and proteomic expression 
levels. In the ischemia/reperfusion rabbit heart model, 
functional annotation clustering analysis using an enrich-
ment score <2.0 and P > 0.05, revealed down-regulation 
of mitochondrion function and energy production, cofac-
tor catabolism, generation of precursor metabolites of 
energy, cellular carbohydrate metabolism, regulation of 
biosynthesis, as well as the regulation of transcription 
and mitochondrial structure and function [16]. All these 
changes are associated with significantly decreased myo-
cardial function and decreased myocardial cell viability.
A role for mitochondrial transplantation
In summary, our studies demonstrate that following the 
onset of myocardial ischemia there are alterations in 
mitochondrial volume [6], function [6, 8], mitochondrial 
calcium accumulation [4, 5, 12], mitochondrial enzyme 
activity (cytochrome oxidase) [5], mitochondrial com-
plex activity [16], high energy synthesis [6, 8, 12], mtDNA 
[13], the mitochondrial modulated intrinsic cell death 
pathway [17, 18] and mitochondrial transcriptomics and 
proteomics [16, 18, 19]. All these deleterious events occur 
during ischemia and persist subsequent to the restoration 
of tissue reperfusion, resulting in severely compromised 
post-ischemic functional recovery and diminished cellu-
lar viability [4–8, 12, 13, 16–19].
Based on these events occurring during myocardial 
ischemia and reperfusion (Fig.  2) we reasoned that the 
augmentation or replacement of mitochondria altered or 
damaged during ischemia with intact viable mitochon-
dria may allow for myocardial cell rescue. We speculated 
that mitochondria isolated from a non-ischemic area in 
the patient’s own body and then transplanted into the 
ischemic region would provide a means to supplement 
the mitochondrial functions injured during ischemia and 
allow for myocardial recovery [19, 20].
Mitochondria isolation and purification
To allow for clinical use of mitochondria for transplanta-
tion, the isolation and purification of mitochondria must 
be timely. Most cardiac surgical procedures last 40  min 
to several hours in duration. In the longer procedures, 
established methods for isolating mitochondria, which 
generally take >90 min, may be adequate [21–26]. How-
ever, for practical usage in procedures taking less than 
an hour, these long duration isolation procedures are 
impractical.
To meet the clinical needs of surgery, we have devel-
oped a rapid method for the isolation and purification of 
mitochondria that can be performed in less than 30 min 
(Fig. 3) [27]. The major benefits of this protocol are that 
it incorporates a standardized tissue dissociation process 
that allows for uniform and consistent homogenization of 
tissue that is not easily achieved with manual homogeni-
zation methods. In addition, we use differential filtration 
rather than centrifugation. The use of filtration elimi-
nates time consuming and repetitive centrifugation steps 
allowing for more rapid isolation of highly purified, viable 
and respiration competent mitochondria.
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In brief, two small pieces of tissue are collected from 
a non-ischemic source. For our experiments, we iso-
lated mitochondria from the pectoralis major muscle. 
This mimics the surgical entry point via minimal thora-
cotomy where the pectoralis major muscle is close to 
the incision site and anatomically available. Alternative 
sources such as abdominal rectus muscle can be used 
if a sternotomy is performed. The muscle tissue is dis-
sected free and two small pieces of tissue are obtained 
using a #6 biopsy punch. The tissue is homogenized in a 
volume of 5 mL of isolation buffer (300 mmol/L sucrose, 
10  mmol/L HEPES–KOH, 1  mmol/L EGTA-KOH, pH 
7.4) and then treated to 10 min of Subtilisin A enzymatic 
digestion on ice [27]. The digested tissue is then filtered 
through a series of filters (40, 40 and 10 uM), pre-wetted 
with isolation buffer, and the mitochondria are subse-
quently precipitated by centrifugation at 9×g for 10 min 
at 4 °C [27]. The exact isolation time is set by the 10 min 
enzymatic digestion and the final centrifugation. In our 
hands, this can be accomplished in less than 30  min. 
The mitochondria are counted by hemocytometer or 
by particle counter [27, 28]. The mitochondria are then 
suspended in freshly prepared Respiration Buffer [19, 20, 
27].
In our myocardial protocols, the mitochondria are 
injected into the ischemic myocardium at 7–8 sites 
(0.1 mL per site) [19, 20]. We have observed that greater 
volumes 0.2  mL result in loss of mitochondria due to 
leakage at the site of injection. To inject the mitochon-
dria we use a tuberculin syringe with a 28 G needle. No 
z-stich for wound closing is needed.
We also determine viability and purity in all mito-
chondrial preparations. Mitochondrial viability is deter-
mined by oxygen consumption rates using a Clark-type 
electrode and fluorescent probe analysis. Mitochondrial 
purity is determined firstly by light microscopy using 
fluorescent mitochondrial labels (MitoTracker CMXros) 
and then by transmission electron microscopy [19, 20, 
27].
The need for viable respiration competent mitochondria
We have investigated the efficacy of various sources of 
mitochondria. Our studies have demonstrated that there 
are differences in the absolute number of mitochondria 
that can be isolated from various tissue sources. Based on 
a constant starting weight the absolute number of mito-
chondria isolated in liver is greater than that obtained 
using skeletal muscle is greater than that obtained using 
atrial tissue [19]. Our studies demonstrate that there are 
no differences in the cardioprotective effects or cellu-
lar uptake of mitochondria isolated from various tissue 
sources [19, 20].
Structure
Volume
Calcium accumulation
Complex activity
Oxygen consumption
High energy synthesis
Transcriptomics
Proteomics 
Myocardial dysfunction
Myonecrosis
Transplantation 
of viable 
mitochondria
Myocardial Functional 
recovery
Survival of myocardium
Ischemia Reperfusion
Mitochondrial Alterations
Fig. 2 Myocardial mitochondrial changes occurring during ischemia. The changes to mitochondria occurring during ischemia are noted. These 
changes extend following the restoration of blood flow and oxygen delivery to the myocardium (reperfusion) and significantly decrease myocardial 
function and cell viability. Mitochondrial transplantation (the direct injection of viable exogenous mitochondria) into the ischemic myocardium, just 
prior to reperfusion significantly enhances myocardial function and cell viability
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Mitochondrial sub-populations do not provide added 
cardioprotection. It has been demonstrated that in heart 
muscle there are differences in the oxygen consump-
tion of the mitochondria dependent upon their location 
within the muscle tissue [29, 30]. To investigate the possi-
ble differential effects of the different sub-populations of 
mitochondria on cardioprotection, we have we have used 
total, interfibrillar and sub-sarcolemmal mitochondria 
isolated from the heart and mitochondria isolated from 
liver or skeletal muscle for mitochondrial transplanta-
tion. Our results demonstrate that mitochondrial trans-
plantation provides similar cardioprotection regardless of 
their source [20].
Of prime importance in providing for efficacy of mito-
chondrial transplantation for cardioprotection is mito-
chondrial viability. The need for viable freshly isolated 
mitochondria is imperative. In our studies, we have 
shown that non-viable mitochondria, mitochondrial pro-
teins, mitochondrial complexes, or mitochondrial RNA 
and DNA do not provide cardioprotection [20]. We also 
found that injection of exogenous ATP and ADP does not 
provide any protective effects on the heart, in agreement 
with studies from other investigators establishing that 
exogenous ATP supplementation and/or ATP synthesis 
promoters are ineffective in restoring high energy phos-
phate stores and provide no beneficial effects on post-
ischemic functional recovery [31–33].
Mitochondrial number
In studies performed to optimize the concentration of 
autologous mitochondria for cardioprotection, we have 
used 2 ×  105, 2 ×  106, 2 ×  107 and 2 ×  108 mitochon-
dria per gram tissue (wet weight). The mitochondria 
were injected into the ischemic heart and infarct size 
was determined following 30  min temporary left ante-
rior descending artery occlusion and 120  min reper-
fusion. The area at risk was 30  ±  4  %. Infarct size was 
determined to be 7.9  ±  2.9, 6.3  ±  3.1, 6.8  ±  2.6 and 
6.0 ± 2.7 %, respectively for 2 × 105, 2 × 106, 2 × 107 and 
2 × 108 mitochondria. No significant difference in infarct 
size was determined between groups. This was likely 
due to the small infarct size (7.9 ± 2.9 %) observed when 
using 2 × 105 mitochondria per gram tissue wet weight. 
In all of our studies, we suspended the mitochondria in a 
final volume of 1 mL and inject at 8–10 sites within the 
area at risk. Mitochondrial concentrations >2 × 108 were 
Pectoralis Major
Mini-Thoracotomy
Sternotomy
Rectus Abdominis
Homogenize tissue
Protease digestion
40 um
40 um
10 um
High speed 
centrifuge
Time (min.)             
Filtration
0
1
11
13
15
17
30
Fig. 3 Mitochondrial isolation. Our protocol for mitochondrial isolation is illustrated. In brief a mini-thoracotomy or a sternotomy is performed and 
tissue is obtained from either pectoralis major or from rectus abdominous muscle. The amount of tissue is small and is shown in comparison to 
an American 10 cent piece. Mitochondria are isolated. Our methodology for mitochondrial isolation is shown [27]. Mitochondrial isolation can be 
performed in less than 30 min. Quality control parameters for mitochondrial isolation and transplantation have been established [28]
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not entirely suspended in 1 mL buffer; so, these concen-
trations were not employed [personal communication 
McCully Lab].
Our studies suggest that the number of mitochondria 
needed for cardioprotection is not a function of the abso-
lute number of mitochondria residing within the cell. In 
cardiomyocytes the mitochondria constitute 30 % of the 
total myocardial cell volume; however, only a small frac-
tion of this number appears to be needed for cardiopro-
tection following ischemia and reperfusion.
Mitochondrial delivery
We have reported the delivery of mitochondria via direct 
injection. This route is simple and can be performed 
readily and efficiently using a tuberculin syringe with 
a standard 18  G needle [19, 20]. In cardiac procedures 
this approach allows for distribution without the need 
for additional suturing and injury to the myocardium. 
We have found that multiple 100  uL injection volumes 
remain within the tissue and no leakage is apparent [20].
In tissue cultures, we used co-incubation as a means 
for mitochondrial transfer. Cells are cultured in 24 well 
plates (5000/well) for 24  h in cell culture media. The 
media is then removed and freshly isolated mitochondria 
are resuspended in fresh cell culture media and then ali-
quots are layered onto the cells with the desired concen-
tration of mitochondria (1 × 107/well in 0.5 mL) [19, 34]. 
This method is effective and uptake is easily achieved.
Mitochondria can be pre-labelled prior to co-incu-
bation. We have used MitoTracker Red CMX Ros 
(100  nmol/L), and other labels [19, 34]. In brief, mito-
chondria are labelled for 10  min at 4  °C and then the 
mitochondria are washed four times by centrifuga-
tion and resuspension in isolation buffer contain-
ing 300  mmol/L sucrose, 10  mmol/L HEPES–KOH, 
1 mmol/L EGTA-KOH, pH 7.4 [19, 34]. In the last wash 
we keep the supernatant and use this in control samples 
to ensure that no free label remains and can be demon-
strated in micrographs.
Mitochondrial uptake
To determine the potential mechanisms by which mito-
chondria could be internalized by cardiomyocytes, stud-
ies were performed using specific blockers based on their 
wide use and established selectivity [34]. Our studies 
demonstrated that mitochondrial internalization by car-
diomyocytes occurs through actin-dependent endocy-
tosis [30]. Internalization of autologous mitochondria 
was not associated with tunneling nanotubes, caveola-
dependent or clathrin-dependent endocytosis. The inter-
nalized mitochondria did not co-localize with lysosomal 
or autophagocytosis markers [34]. This is in agreement 
with the mechanism first proposed by Margulis [35], 
who hypothesized that the mitochondrion, existing as 
a prokaryotic cell was engulfed by a eukaryotic host cell 
and then was established within that cell. In  vivo many 
methods of mitochondrial transfer between cells have 
been postulated; however, our observations show that 
externally presented mitochondria are readily inter-
nalized by a wide variety of host cells. This contrasts to 
intercellular mitochondrial transfer mechanisms where 
these organelles are transferred from one cell to another 
through cylindrical conduits (tunneling nanotubes) [36–
39]. Although it is possible that intercellular mitochon-
drial transfer occurs after endosomal internalization, this 
particular mechanism does not seem to be involved with 
internalization of exogenous mitochondria.
Mitochondrial distribution
In rabbit heart studies we have shown that injected mito-
chondria labeled MitoTracker Orange CMTMRos are 
viable and are visible at the site of the injection and are 
distributed >2–3  mm distant from the site of injection 
[19, 20].
The transplanted autologously-derived mitochon-
dria are initially observed in the interstitial spaces sur-
rounding cardiomyocytes, with extensive epicardial to 
sub-endocardial distribution. These transplanted mito-
chondria significantly increase tissue ATP content in 
the heart. At 1–2  h after injection, the transplanted 
mitochondria are detectable within cardiomyocytes and 
can be observed residing near the sarcolemma between 
Z-lines of the sarcomeres. Internalization into cardio-
myocytes has been confirmed using mitochondria iso-
lated from HeLa cells (human) in rabbit heart. The use 
of human mitochondria in the rabbit model allowed for 
the differentiation between native rabbit mitochondria 
and transplanted human mitochondria based on immune 
reactivity to a monoclonal anti-human mitochondria 
antibody [19, 20]. Transmission electron microscopy 
studies using immuno-gold staining verified that trans-
planted mitochondria are internalized into cardiomyo-
cytes [19, 20].
In in vitro cardiomyocyte studies we have shown that 
the uptake of mitochondria is linear and time depend-
ent. The transplanted mitochondria significantly increase 
(p  <  0.05) cardiomyocyte ATP content as compared to 
control in both neonatal and adult cardiomyocytes [19, 
20, 34].
Immune and auto‑immune reactions of mitochondrial 
transplantation
The transplantation of autogeneic mitochondria for the 
amelioration of myonecrosis offers a unique therapeutic 
potential. The isolation and preparation of autogeneic 
mitochondria from a patient’s own body would prevent 
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inflammation and rejection. Our studies to date have 
demonstrated significantly decreased inflammatory 
markers (TNFα, IL-6, IL-10 MCP-1 and hsCRP) when 
compared to untreated regional ischemia [19]. Necropsy 
of hearts at 28 days after mitochondrial injection showed 
no inflammation or evidence of injury. At the same time, 
there was no increase in white blood cell counts in any 
animal receiving mitochondrial transplantation [19].
Multiplex analyses indicated that transplantation of 
autologous mitochondria significantly upregulated epi-
dermal growth factor (EGF), growth-related oncogene 
(GRO), IL-6 and monocyte chemotactic protein-3 (MCP-
3) expression. These cytokines have been shown to play 
key roles in angiogenesis, arteriogenesis, immunomodu-
lation, progenitor cell migration, prevention of apoptosis 
and enhanced cell salvage and post-ischemic functional 
recovery (19). Previous studies have demonstrated that 
EGF plays an important role in ischemic injury protec-
tion in the heart through the stimulation of cell growth, 
proliferation, and migration [40–42]. GRO and Il-6 act 
together following infarction to improve cardiac func-
tion through the reconstitution of tissue mass. In this 
process IL-6 acts as a chemo-attractant which allows for 
enhanced vascularization, protection against cardiomyo-
cyte apoptosis. These actions have been demonstrated 
to improve functional recovery in the heart [40, 42]. 
EGF, GRO and IL-6 act with MCP-3 to improve cardiac 
remodeling independent of cardiac myocyte regeneration 
[43].
On the other hand, no pro-inflammatory cytokines 
were upregulated by this treatment. There was no 
upregulation of cytokines associated with the immune 
response that is seen in patients with acute heart trans-
plantation rejection (IL-1, IL-4, IL-6, IL-12, IL-18, IP-10, 
macrophage inflammatory protein (MIP-1α and MIP-1β) 
[19].
To test for autoimmunity we have used a specific assay 
to determine mitochondrial autoimmune response. The 
assay is used in the diagnosis of primary biliary cirrhosis 
and the complete assay is described [19]. In brief, serum 
is collected from test animals and is used for indirect 
immunofluorescent assay for the detection of antibod-
ies directed against mitochondrial antigens (AMAs). 
Hep-2 cells are used as substrate. Human serum from a 
patient with primary biliary cirrhosis, containing a high 
titer of AMA, is used as a positive control. Diluted rab-
bit sera and human serum are incubated with the Hep-2 
cells for 1 h at room temperature and the unbound anti-
bodies are removed by three successive washes with PBS, 
Bound antibodies are detected with secondary antiserum 
to detect AMA [19]. Our results demonstrate that the 
injection of mitochondria, even at high concentrations 
1 × 1010 does not induce any autoimmune response [19].
It is also of relevance that we did not find any signs of 
myocardial arrhythmia associated with mitochondrial 
transplantation. Our results, using serial long term ECG, 
QRS duration, and corrected QT interval, show no evi-
dence of ventricular wall motion disturbances, left ventri-
cle hypertrophy, valve dysfunction, fibrosis, or pericardial 
effusion at 4  weeks following transplantation of autoge-
neic mitochondria [19]. To ensure no arrhythmia was 
associated with mitochondrial transplantation we also 
performed optical mapping studies in the rat heart using 
4.2 × 108 mitochondria. The concentration of mitochon-
dria was 8.4  ×  107/g tissue wet weight as compared to 
2 × 105 to 2 × 107/g tissue wet weight, so that any acute 
arrhythmogenic responses would be observed. These 
studies failed to show any abnormal impulse propagation 
on the myocardial surface associated with mitochondrial 
transplantation.
Mitochondrial alterations affecting cardioprotection
In our studies in the isolated perfused heart and the 
in  situ blood perfused heart model we have followed 
a similar protocol (Fig.  4). In this protocol the heart is 
exposed using a mini-thoracotomy or a sternotomy. 
Muscle tissue from the pectoralis major tissue is har-
vested and used for mitochondrial isolation as described 
in Fig. 3. The heart is then made ischemic by temporar-
ily snaring the left anterior descending artery to cease 
blood flow to the left ventricle. This is performed by pass-
ing a Prolene suture around the left anterior descending 
coronary artery with a cutting needle and passing both 
ends of the suture through a small vinyl tube to form a 
snare which was then pulled tight and fixed with a mos-
quito clamp [19, 20]. Following 29 min regional ischemia, 
hearts received eight, 0.1 mL injections delivered to the 
left ventricle of either vehicle alone or mitochondria sus-
pended in vehicle. The mitochondria were injected into 
the epicardium using a tuberculin syringe with a 28  g 
needle. The snare was then released and coronary blood 
flow through the left anterior descending coronary artery 
was re-established. The hearts were allowed to recover 
and functional and biochemical data were collected. In 
the in situ blood perfused models we have used 4 weeks 
recovery [19]. In the isolated perfused heart 2 h reperfu-
sion is used to allow for estimation of infarct size [20].
Once transplanted, mitochondria maintain viability 
and function, increasing ATP levels and ATP synthesis 
and, at least some of these remain in myocardial cells 
in situ for 28 days [19, 20, 34]. This is in contrast to pre-
sent xeno- and allo-transplanted cells that provide lim-
ited improvement in heart function and are ultimately 
rejected leading to the loss of transplanted cells and 
recurrence of heart failure, despite the use of anti-rejec-
tion pharmaceuticals [44, 45].
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The transplanted mitochondria also act to alter the 
myocardial proteome. Our studies in the in  situ rab-
bit heart model show that there were distinct protein 
expression patterns between hearts receiving mitochon-
drial transplantation and control hearts receiving vehicle 
only. These changes occur rapidly after mitochondrial 
transplantation. At 10 min post injection we were able to 
detect changes in myocardial function by electrocardio-
gram and echo cardiographic analysis [19]. Myocardial 
tissue isolated from hearts treated with mitochondria 
transplantation showed significant alterations in the 
mitochondrial proteome at this time. Functional annota-
tion clustering (P  <  0.05, Enrichment Score  >  2.0) indi-
cated that protein pathways for the mitochondrion and 
the generation of precursor metabolites for energy and 
cellular respiration were significantly enriched in hearts 
receiving mitochondrial transplantation as compared to 
control hearts receiving vehicle only [19]. These changes 
in the proteome likely aided the long-term recovery of 
the myocardium through the up-regulation of mito-
chondrial associated pathways leading to enhanced high 
energy synthesis and mitochondrial repair.
In recent studies, we have shown that mitochondrial 
transplantation not only rescues cell function, increasing 
cellular ATP content and mitochondrial oxygen consump-
tion, but also replaces damaged mitochondrial DNA [34]. 
These studies were performed in vitro using human HeLa 
cells deleted of mitochondrial DNA (p0 rho HeLa cells). 
HeLa p0 cells are depleted of mtDNA through serial pas-
sage with low concentrations of ethidium bromide [46]. 
HeLa p0 cells due to the deletion of mitochondrial DNA 
are incapable of synthesizing the mitochondrial encoded 
sub-protein constituents of the electron transport chain 
and as a result provide energy generation through fer-
mentation but lack oxygen consumption capacity due 
to depletion of electron transport chain sub-proteins 
encoded by mtDNA. As a result of this inability to utilize 
the electron transport chain HeLa p0 cell mitochondria 
have no oxygen uptake and ATP synthesis is generated 
only by glycolysis. Our studies demonstrate that co-incu-
bation of HeLa p0 cells with mitochondria isolated from 
HeLa cells containing intact mtDNA rescues HeLa p0 
cell function by significantly increasing ATP content and 
oxygen consumption rates [34]. The enhanced intracel-
lular ATP content was significantly increased in HeLa p0 
cells following co-incubation with mitochondria at 24, 48, 
72 h and 1 and 2 weeks [34]. Quantitative real-time RT-
PCR analysis demonstrated that while there was no mito-
chondrial DNA in HeLa p0 cells, mitochondrial DNA was 
detected in HeLa p0 cells with internalized mitochondria 
from HeLa cells with intact DNA [34].These experiments 
demonstrated that mitochondrial transplantation can be 
used therapeutically to rescue cell function and replace 
damaged mitochondrial DNA.
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Fig. 4 Experimental outline for mitochondrial transplantation studies [19, 20]
Page 10 of 13McCully et al. Clin Trans Med  (2016) 5:16 
Mechanism of cardioprotection
The mechanisms through which the transplantation of 
autologous mitochondria provides for cardioprotec-
tion clearly involves both enhanced ATP production 
and alterations in the proteome, cytokine induction and 
replacement of damaged mtDNA. We speculate that 
these effects act to provide cardioprotection in two over-
lapping phases; (1): an immediate cardioprotective phase 
and (2): a late cardioprotective phase.
The immediate cardioprotective phase occurs dur-
ing the first 10 min of reperfusion and is associated with 
transplanted mitochondria being closely associated with 
cardiac cells. This close association significantly enhances 
total tissue ATP and cardiac cell enrichment of differen-
tially expressed proteins associated with mitochondrial 
pathways responsible for the generation of precursor 
metabolites associated with energy and cellular respira-
tion. These modulations would allow for cardiac cells 
to respond to the ischemic insult during the immedi-
ate phase of reperfusion by providing needed ATP and 
needed up-regulation of mitochondrial pathways and 
as a consequence, would allow for cardiac cell rescue 
and enhanced post-ischemic functional recovery. These 
effects occurring during early reperfusion would then act 
in concert with late-cardioprotective effects to enhance 
long term viability and function.
The late-cardioprotective phase is evident prior to 1 h 
following mitochondrial transplantation. In this phase 
mitochondria are internalized into cardiac cells. ATP 
synthesis and oxygen consumption rate in cardiac cells is 
significantly enhanced. We hypothesize that it is during 
this late phase when the mitochondria are internalized by 
the cells that the mitochondria act to repair mitochon-
drial DNA damaged during ischemia. Support for this 
mechanism comes from our studies demonstrating that 
myocardial function is enhanced and myocardial infarct 
size is significantly decreased and that these alterations 
are evident and stable for at least 28 days post-injection, 
the duration of our current studies [19, 34].
Mitochondrial transplantation in other organs
Our studies have pioneered the efficacy of mitochon-
drial transplantation using direct tissue injection [19, 
20]. While these studies have been focused mostly on the 
myocardium, we have also performed studies to show 
that mitochondrial transplantation can be performed in a 
variety of cell types using autogeneic, allogeneic and xen-
ogeneic mitochondria (Fig.  5). Our studies demonstrate 
that mitochondrial transfer can be performed in neonatal 
and adult cardiomyocytes, skeletal muscle cells, human 
cells (HeLa, HeLa p0 vascular endothelial cells and mixed 
neuronal cell types [34]. The efficacy of uptake appears to 
be similar in all cell types we have examined with mito-
chondria being internalized in a time-dependent manner. 
Mitochondrial internalization in all cell types is evident 
following 1 h co-incubation and is significantly increased 
following 4 and 24 h co-incubation [19, 34]. The increase 
in mitochondrial internalization is correlated with 
increased cellular ATP content and cellular oxygen con-
sumption [19, 34]. The uptake and action of mitochon-
dria is similar to that obtained using microinjection. 
King and Attardi [47] have previously demonstrated that 
micro-injection of mitochondria into cell lines depleted 
of their own mitochondrial DNA allowed for the replace-
ment of the resident mtDNA by exogenous mtDNA.
Mitochondrial transplantation is also efficacious in 
other disease models (Table  1). Elliott et  al. [48] have 
recently used mitochondrial transplantation to enhance 
drug sensitivity in human breast cancer cells. The authors 
demonstrated that mitochondria isolated from human 
immortalized, untransformed mammary epithelia cell 
line, MCF-12A, and co-incubated with human breast 
cancer cell lines resulted in the uptake of untransformed 
cell line mitochondria inhibiting cancer cell proliferation 
Fig. 5 Transplanted mitochondria are internalized by a variety of cell types: a neonatal rat cardiomyocytes, b adult rat cardiomyocytes, c rat skeletal 
myoblasts, d embryonic rat neurons and e mixed embryonic rat neuronal cells. Internalized pHrodo Red-labeled rat liver mitochondria (red) follow-
ing 4 h co-culture are shown in each cell type. In all images the blue stain is DAPI, alpha-actinin 2 is depicted in green. Scale bars are 10 um
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and increasing the sensitivity of the cancer cells to anti-
cancer agents.
Chang et  al. [49] has used peptide-mediated mito-
chondrial delivery to rescue cell function in cells harbor-
ing the mitochondrial DNA mutation MERRF A8344G. 
This methodology delivers isolated mitochondria to cells 
by first conjugating isolated mitochondria with Pep-1, a 
member of the cell-penetrating peptide family. Recently 
this same group has used this methodology to replace 
damaged mitochondria in a rat model of Parkinson’s dis-
ease [50]. The authors showed that Pep-1 conjugated mito-
chondrial transplantation into the midbrain of neurotoxin 
induced cells and Parkinson’s disease rat models signifi-
cantly enhanced mitochondria function and partially ame-
liorated the degeneration of dopaminergic neurons.
Lin et al. [51] have shown that a splenic injection of iso-
lated mitochondria significantly ameliorated liver ischemia/
reperfusion injury in the rat, significantly decreasing serum 
enzyme markers of liver damage and liver cell apoptosis.
Kitani et  al. [52] showed that isolated mitochondria 
are taken up and internalized by rat cardio-myoblasts 
and rescued mitochondrial respiratory function and 
improved the cellular viability.
The examples of the diseases and syndromes and/or 
clinical situations in which mitochondrial transplantation 
can be used are too many to discuss within this review. 
The effects of mitochondrial transplantation on mito-
chondrial disorders with associated heteroplasmy require 
more in depth analysis than has been currently provided. 
A key feature in this analysis is the source and use of the 
mitochondria. In cases such as ischemia/reperfusion 
injury or compartment injury to name just two, the use 
of autologous mitochondria would be effective only no 
alteration in the mitochondrial genome that could affect 
recovery was present. However, in the cases where mito-
chondrial DNA defects are present, the use of allo- and 
xeno-genetic mitochondria would be more appropri-
ate. This would allow for the replacement of damaged 
mtDNA with intact functional exogenous mtDNA. At 
present there is not sufficient data for the recommenda-
tion of either allo- or xeno-genetic mitochondria as no 
immune or auto-immune data is available. The use of 
multiple treatments has not been reviewed nor has any 
toxicological analysis been performed as yet. Despite 
these obvious caveats, the therapeutic potential of mito-
chondrial transplantation is great and it is likely that this 
new treatment modality will significantly decrease mor-
bidity and mortality associated with mitochondrial alter-
ation or dysfunction.
Conclusions
We have focused our research on myocardial ischemia 
and myocardial function in the adult heart; however, we 
have also shown that mitochondrial uptake occurs in 
neonatal cardiomyocytes, skeletal muscle, human (HeLa) 
cells and mixed neuronal cell cultures. The methodolo-
gies we present are uncomplicated and can be performed 
in any laboratory with limited investment. The major 
consideration for efficacy is that the mitochondria used 
in transplantation must be viable and intact to allow for 
uptake, internalization and efficacy.
The isolation and preparation of autogeneic mito-
chondria is rapid and purified mitochondrial are avail-
able within 30 min, a time-frame within the clinical time 
frame for use in surgery. The transplantation of mito-
chondria is not pro-arrhythmic and does not induce 
immune or auto-immune responses. Mitochondrial 
transplantation provides an efficacious cardioprotective 
protocol that can be used either as an exclusive interven-
tion to ameliorate myonecrosis and enhance myocardial 
function or could be used as a primary intervention prior 
to subsequent auto-, allo- or xeno-geneic cellular regen-
erative interventions requiring extended times for cell 
isolation, purification and expansion.
The uptake of mitochondria appears to be universal. 
We foresee that mitochondrial transplantation will be a 
Table 1 Mitochondrial transplantation
Tissue Heart Heart Liver Brain
Animal model Rabbit Rabbit Rat Rat
Experimental 
model
Langendorff perfused 
heart
In situ, blood perfused In situ, blood perfused In situ brain
Injury model Ischemia/reperfusion Ischemia/reperfusion Ischemia/reperfusion Parkinson’s disease
Mitochondria Unmodified Unmodified Unmodified Conjugated with PEP-1
Delivery Direct injection Direct injection Direct injection Direct injection
Outcome Enhanced myocardial 
function following 
ischemia, enhanced  
cell viability
Enhanced myocardial 
function following 
ischemia, enhanced 
cell viability
Decreased liver tissue 
injury and apoptosis
Peptide-mediated mitochondrial transplantation 
lessened Parkinson’s disease movement  
disorder and attenuated the deterioration of  
dopaminergic neurons
Reference McCully et al. [20] Masuzawa et al. [19] Lin et al. [51] Chang et al. [50]
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valued treatment in the armamentarium of all clinicians 
and surgeons for the treatment of varied ischemic disor-
ders, mitochondrial diseases and related disorders.
All experiments described in this paper were approved 
by the Beth Israel Deaconess Medical Center Animal 
Care and Use Committee (032-2010, 065-2012), the Bos-
ton Children’s Hospital Animal Care and Use Committee 
(005-2013, 014-2013) and or, the Harvard Medical School 
Animal Care and Use Committee and conformed to the 
US National Institutes of Health (NIH) guidelines regu-
lating the care and use of laboratory animals (NIH pub-
lication no. 5377-3, 1996). All research was performed in 
accordance to the American Physiological Society Guid-
ing Principles in the Care and Use of Animals and the 
revised Animals (Scientific Procedures) Act 1986 in the 
UK and Directive 2010/63/EU in Europe.
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